Results 151 to 160 of about 116,720 (351)

Evaluation of the performance of ChatGPT‐4 and ChatGPT‐4o as a learning tool in endodontics

open access: yesInternational Endodontic Journal, EarlyView.
Abstract Aims The aim of this study was to evaluate the accuracy and consistency of responses given by two different versions of Chat Generative Pre‐trained Transformer (ChatGPT), ChatGPT‐4, and ChatGPT‐4o, to multiple‐choice questions prepared from undergraduate endodontic education topics at different times of the day and on different days ...
Esra Arılı Öztürk   +2 more
wiley   +1 more source

Mass‐Standardised Differential Antibody Binding to a Spectrum of SARS‐CoV‐2 Variant Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4/5, BA.2.75 and BA.2.12.1 Variants—Antibody Immunity Endotypes

open access: yesImmunology, EarlyView.
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton   +6 more
wiley   +1 more source

Patients' Experiences of Day Surgery: A Qualitative Systematic Review

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To examine how patients experience day surgery. Design Systematic review using Thomas and Harden's framework for synthesis and analysed through Ricoeur's theory of interpretation. Methods and Data Sources Systematic searches in MEDLINE, CINAHL and EMBASE (September 2023) identified qualitative studies focusing on patients' lived ...
Josephine Ransborg Sig   +4 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui   +15 more
wiley   +1 more source

The TRIP database showed most Acute Respiratory Infections questions were already addressed by Cochrane reviews [PDF]

open access: yes, 2019
Brassey, Jon   +4 more
core   +1 more source

Oral Health and Pneumonia in Adults With Intellectual and Developmental Disabilities: A Scoping Review

open access: yesJournal of Intellectual Disability Research, EarlyView.
ABSTRACT Introduction Pneumonia is a leading cause of death for people with intellectual and developmental disabilities (IDD), who also have increased risk of oral disease. Given the known relationship between oral disease and pneumonia in similar populations, this review aims to explore what is known about the association between oral health and ...
Katrina Byrne   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy